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Abstract
Background: The National Early Warning Score (NEWS2) is currently recommended in the UK for the risk
stratification of COVID-19 patients, but little is known about its ability to detect severe cases. We aimed to evaluate
NEWS2 for the prediction of severe COVID-19 outcome and identify and validate a set of blood and physiological
parameters routinely collected at hospital admission to improve upon the use of NEWS2 alone for medium-term
risk stratification.
Methods: Training cohorts comprised 1276 patients admitted to King’s College Hospital National Health Service
(NHS) Foundation Trust with COVID-19 disease from 1 March to 30 April 2020. External validation cohorts included
6237 patients from five UK NHS Trusts (Guy’s and St Thomas’ Hospitals, University Hospitals Southampton, University
Hospitals Bristol and Weston NHS Foundation Trust, University College London Hospitals, University Hospitals
Birmingham), one hospital in Norway (Oslo University Hospital), and two hospitals in Wuhan, China (Wuhan Sixth
Hospital and Taikang Tongji Hospital). The outcome was severe COVID-19 disease (transfer to intensive care unit
(ICU) or death) at 14 days after hospital admission. Age, physiological measures, blood biomarkers, sex, ethnicity,
and comorbidities (hypertension, diabetes, cardiovascular, respiratory and kidney diseases) measured at hospital
admission were considered in the models.
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Results: A baseline model of ‘NEWS2 + age’ had poor-to-moderate discrimination for severe COVID-19 infection at
14 days (area under receiver operating characteristic curve (AUC) in training cohort = 0.700, 95% confidence interval
(CI) 0.680, 0.722; Brier score = 0.192, 95% CI 0.186, 0.197). A supplemented model adding eight routinely collected
blood and physiological parameters (supplemental oxygen flow rate, urea, age, oxygen saturation, C-reactive
protein, estimated glomerular filtration rate, neutrophil count, neutrophil/lymphocyte ratio) improved discrimination
(AUC = 0.735; 95% CI 0.715, 0.757), and these improvements were replicated across seven UK and non-UK sites.
However, there was evidence of miscalibration with the model tending to underestimate risks in most sites.
Conclusions: NEWS2 score had poor-to-moderate discrimination for medium-term COVID-19 outcome which raises
questions about its use as a screening tool at hospital admission. Risk stratification was improved by including
readily available blood and physiological parameters measured at hospital admission, but there was evidence of
miscalibration in external sites. This highlights the need for a better understanding of the use of early warning
scores for COVID.
Keywords: NEWS2 score, Blood parameters, COVID-19, Prediction model
Key messages
 The National Early Warning Score (NEWS2),
currently recommended for stratification of severe
COVID-19 disease in the UK, showed poor-to-
moderate discrimination for medium-term outcomes
(14-day transfer to intensive care unit (ICU) or
death) amongst COVID-19 patients.
 Risk stratification was improved by the addition of
routinely measured blood and physiological
parameters routinely at hospital admission
(supplemental oxygen, urea, oxygen saturation, C-
reactive protein, estimated glomerular filtration rate,
neutrophil count, neutrophil/lymphocyte ratio)
which provided moderate improvements in a risk
stratification model for 14-day ICU/death.
 This improvement over NEWS2 alone was
maintained across multiple hospital trusts, but the
model tended to be miscalibrated with risks of
severe outcomes underestimated in most sites.
 We benefited from existing pipelines for informatics
at King’s College Hospital such as CogStack that
allowed rapid extraction and processing of electronic
health records. This methodological approach
provided rapid insights and allowed us to overcome
the complications associated with slow data
centralisation approaches.
Background
As of 9 December 2020, there have been > 67 million
confirmed cases of COVID-19 disease worldwide [1].
While approximately 80% of infected individuals have
mild or no symptoms [2], some develop severe COVID-
19 disease requiring hospital admission. Within the
subset of those requiring hospitalisation, early identifica-
tion of those who deteriorate and require transfer to an
intensive care unit (ICU) for organ support or may die is
vital.
Currently, available risk scores for deterioration of
acutely ill patients include (i) widely used generic ward-
based risk indices such as the National Early Warning
Score (NEWS2, [3]), (ii) the Modified Sequential Organ
Failure Assessment (mSOFA) [4] and Quick Sequential
Organ Failure Assessment [5] scoring systems, and (iii)
the pneumonia-specific risk index, CURB-65 [6] which
combines physiological observations with limited blood
markers and comorbidities. NEWS2 is a summary score
of six physiological parameters or ‘vital signs’ (respira-
tory rate, oxygen saturation, systolic blood pressure,
heart rate, level of consciousness, temperature and sup-
plemental oxygen dependency) used to identify patients
at risk of early clinical deterioration in the United
Kingdom (UK) National Health Service (NHS) hospitals
[7, 8] and primary care. Some components (in particular,
patient temperature, oxygen saturation, and supplemen-
tal oxygen dependency) have been associated with
COVID-19 outcomes [2], but little is known about their
predictive value for COVID-19 disease severity in hospi-
talised patients [9]. Additionally, a number of COVID-
19-specific risk indices are being developed [10, 11] as
well as unvalidated online calculators [12], but generalis-
ability is unknown [13]. A Chinese study has suggested a
modified version of NEWS2 with the addition of age
only [14] but without any data on performance. With
near-universal usage of NEWS2 in UK NHS Trusts since
March 2019 [15], a minor adaptation to NEWS2 would
be relatively easy to implement.
As the SARS-Cov2 pandemic has progressed, a num-
ber of risk prediction models to support clinical deci-
sions, triage, and care in hospitalised patients have been
proposed [13] incorporating potentially useful blood bio-
markers [2, 16–19]. These include neutrophilia and lym-
phopenia, particularly in older adults [11, 18, 20, 21];
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neutrophil-to-lymphocyte ratio [22]; C-reactive protein
(CRP) [13]; lymphocyte-to-CRP ratio [22]; markers of
liver and cardiac injury such as alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and cardiac
troponin [23]; and elevated D-dimers, ferritin and fi-
brinogen [2, 6, 8].
Our aim is to evaluate the NEWS2 score and identify
which clinical and blood biomarkers routinely measured
at hospital admission can improve medium-term risk
stratification of severe COVID-19 outcome at 14 days
from hospital admission. Our specific objectives were as
follows:
1. To explore independent associations of routinely
measured physiological and blood parameters
(including NEWS2 parameters) at hospital
admission with disease severity (ICU admission or
death at 14 days from hospital admission), adjusting
for demographics and comorbidities
2. To develop a prediction model for severe COVID-
19 outcomes at 14 days combining multiple blood
and physiological parameters
3. To compare the discrimination, calibration, and
clinical utility of the resulting model with NEWS2
score and age alone using (i) internal validation and
(ii) external validation at seven UK and
international sites
A recent systematic review found that most existing
prediction models for COVID-19 had a high risk of bias
due to non-representative samples, model overfitting, or
poor reporting [13]. The analyses presented here build
upon our earlier work [24] which suggested that adding
age and common blood biomarkers to the NEWS2 score
could improve risk stratification in patients hospitalised
with COVID-19. While incorporating external valid-
ation, this preliminary work was limited in that the
training sample comprised 439 patients (the cohort
available at the time of model development). In the
present study, we (i) expand the cohort used for model
development to all 1276 patients at King’s College
Hospital (KCH), (ii) use hospital admission (rather than
symptom onset) as the index date, (iii) consider shorter-
term outcomes (3-day ICU/death), (iv) improve the
reporting of model calibration and clinical utility, and




The KCH training cohort (n = 1276) was defined as all
adult inpatients testing positive for severe acute respira-
tory syndrome coronavirus 2 (SARS-Cov2) by reverse
transcription polymerase chain reaction (RT-PCR)
between 1 March and 31 April 2020 at two acute hospi-
tals (King’s College Hospital and Princess Royal Univer-
sity Hospital) in South East London (UK) of Kings
College Hospital NHS Foundation Trust (KCH). All pa-
tients included in the study had symptoms consistent
with COVID-19 (e.g. cough, fever, dyspnoea, myalgia,
delirium, diarrhoea). For external validation purposes,
we used seven cohorts:
1. Guy’s and St Thomas’ Hospital NHS Foundation
Trust (GSTT) of 988 cases (3 March 2020 to 26
August 2020)
2. University Hospitals Southampton NHS Foundation
Trust (UHS) of 633 cases (7 March to 6 June 2020)
3. University Hospitals Bristol and Weston NHS
Foundation Trust (UHBW) of 190 cases (12 March
to 11 June 2020)
4. University College Hospital London (UCH) of 411
cases (1 February to 30 April 2020)
5. University Hospitals Birmingham (UHB) of 1037
cases (1 March to 31 June 2020)
6. Oslo University Hospital (OUH) of 163 cases (6
March to 13 June 2020)
7. Wuhan Sixth Hospital and Taikang Tongji Hospital
of 2815 cases (4 February 2020 to 30 March 2020)
Data were extracted from structured and/or unstruc-
tured components of electronic health records (EHR) in
each site as detailed below.
Measures
Outcome
For all sites, the outcome was severe COVID-19 disease
at 14 days following hospital admission, categorised as
transfer to the ICU/death (WHO-COVID-19 Outcomes
Scales 6–8) vs. not transferred to the ICU/death (scales
3–5) [25]. For nosocomial patients (patients with symp-
tom onset after hospital admission), the endpoint was
defined as 14 days after symptom onset. Dates of hos-
pital admission, symptom onset, ICU transfer, and death
were extracted from electronic health records or ascer-
tained manually by a clinician.
Blood and physiological parameters
We included blood and physiological parameters that
were routinely obtained at hospital admission and which
are routinely available in a wide range of national and
international hospital and community settings. Measures
available for fewer than 30% of patients were not consid-
ered (including Troponin-T, Ferritin, D-dimers and
glycated haemoglobin (HbA1c), Glasgow Coma Scale
score). We excluded creatinine since this parameter cor-
relates highly (r > 0.8) with, and is used in the derivation
of, estimated glomerular filtration rate. We excluded
Carr et al. BMC Medicine           (2021) 19:23 Page 3 of 16
white blood cell count (WBCs) which is highly corre-
lated with neutrophil and lymphocyte counts.
The candidate blood parameters therefore comprised
albumin (g/L), C-reactive protein (CRP; mg/L), esti-
mated glomerular filtration rate (GFR; mL/min),
haemoglobin (g/L), lymphocyte count (× 109/L), neutro-
phil count (× 109/L), platelet count (PLT; × 109/L),
neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-
CRP ratio [22], and urea (mmol/L). The candidate
physiological parameters included the NEWS2 total
score, as well as the following parameters: respiratory
rate (breaths per minute), oxygen saturation (%), supple-
mental oxygen flow rate (L/min), diastolic blood pres-
sure (mmHg), systolic blood pressure (mmHg), heart
rate (beats/min), and temperature (°C). For all parame-
ters, we used the first available measure up to 48 h fol-
lowing hospital admission.
Demographics and comorbidities
Age, sex, ethnicity and comorbidities were considered.
Self-defined ethnicity was categorised as White vs. non-
White (Black, Asian, or other minority ethnic) and
patients with ethnicity recorded as ‘unknown/mixed/
other’ were excluded (n = 316; 25%). Binary variables
were derived for comorbidities: hypertension, diabetes,
heart disease (heart failure and ischemic heart disease),
respiratory disease (asthma and chronic obstructive pul-
monary disease (COPD)), and chronic kidney disease.
Data processing
King’s College Hospital
Data were extracted from the structured and unstruc-
tured components of the electronic health record (EHR)
using natural language processing (NLP) tools belonging
to the CogStack ecosystem [26], namely MedCAT [27]
and MedCATTrainer [28]. The CogStack NLP pipeline
captures negation, synonyms, and acronyms for medical
Systematised Nomenclature of Medicine Clinical Terms
(SNOMED-CT) concepts as well as surrounding
linguistic context using deep learning and long short-
term memory networks. MedCAT produces unsuper-
vised annotations for all SNOMED-CT concepts
(Additional file 1: Table S1) under parent terms Clinical
Finding, Disorder, Organism, and Event with disambigu-
ation, pre-trained on MIMIC-III [29]. Starting from our
previous model [30], further supervised training im-
proved detection of annotations and meta-annotations
such as experiencer (is the annotated concept experi-
enced by the patient or other), negation (is the concept
annotated negated or not), and temporality (is the con-
cept annotated in the past or present) with MedCAT-
Trainer. Meta-annotations for hypothetical, historical,
and experiencer were merged into “Irrelevant” allowing
us to exclude any mentions of a concept that did not
directly relate to the patient currently. Performance of
the NLP pipeline for comorbidities mentioned in the
text was evaluated on 4343 annotations in 146 clinical
documents by a clinician (JT). F1 scores, precision, and
recall are presented in Additional file 2: Table S2.
Guy’s and St Thomas’ NHS Foundation Trust
Electronic health records from all patients admitted to
Guy’s and St Thomas’ NHS Foundation Trust who had a
positive COVID-19 test result between 3 March and 21
May 2020, inclusive, were identified. Data were extracted
using structured queries from six complementary
platforms and linked using unique patient identifiers.
Data processing was performed using Python 3.7 [31].
The process and outputs were reviewed by a study
clinician.
University Hospitals Southampton
Data were extracted from the structured components of
the UHS CHARTS EHR system and data warehouse.
Data were transformed into the required format for val-
idation purposes using Python 3.7 [31]. Diagnosis and
comorbidity data of interest were gathered from the
International Statistical Classification of Diseases (ICD-
10) coded data. No unstructured data extraction was re-
quired for validation purposes. The process and outputs
were reviewed by an experienced clinician prior to
analysis.
University Hospitals Bristol and Weston NHS Foundation
Trust
Data were extracted from UHBW electronic health re-
cords system (Medway). ICD-10 codes were used for
diagnosis and comorbidity data. Data were transformed
in line with project specifications and exported for ana-
lysis in Python 3.7 [31].
University College Hospital London
Dates of hospital admission, symptom onset, ICU trans-
fer, and death were extracted from electronic health
records. The outcome (14-day ICU/death) was defined
in UCLH as ‘initiation of ventilatory support (con-
tinuous positive airway pressure, non-invasive ventila-
tion, high-flow nasal cannula oxygen, invasive
mechanical ventilation, or extracorporeal membrane
oxygenation) or death’ which is consistent WHO-
COVID-19 Outcomes Scales 6–8.
Wuhan cohort
Demographic, premorbid conditions, clinical symptoms
or signs at presentation, laboratory data, and treatment
and outcome data were extracted from electronic med-
ical records using a standardised data collection form by
a team of experienced respiratory clinicians, with double
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data checking and involvement of a third reviewer where
there was disagreement. Anonymised data was entered
into a password-protected computerised database.
University Hospitals Birmingham
Dates of hospital admission, symptom onset, ICU trans-
fer, and death were extracted from electronic health
records using the Prescribing Information and Commu-
nications System (PICS) system. The extracted data was
transformed into the required format for validation pur-
poses using Python 3.8 [31]. Diagnosis and comorbidity
data of interest were gathered from ICD-10 coded data.
The outcomes (3- and 14-day ICU/death) were defined
consistent with WHO-COVID-19 Outcomes Scales 6–8.
Oslo University Hospital
All admitted patients with confirmed COVID-19 by
positive SARS-CoV2 PCR were included in a quality
registry. Data input into the register was manual. Regis-
ter data was supplemented with test results from the la-
boratory information system (LIS) by matching exported
Excel files from the register with exported Excel files
from LIS. The fidelity of the match was checked against
the original data source manually for a small number of
patients. Only patients with symptoms consistent with
COVID-19 were included in the study.
Statistical analyses
All continuous parameters were winsorized (at 1% and
99%) and scaled (mean = 0; standard deviation = 1) to
facilitate interpretability and comparability [32]. Loga-
rithmic or square root transformations were applied to
skewed parameters. To explore independent associations
of blood and physiological parameters with 14-day ICU/
death (objective 1), we used logistic regression with
Firth’s bias reduction method [33]. Each parameter was
tested independently, adjusted for age and sex (model 1),
and then additionally adjusted for comorbidities (model
2). P values were adjusted using the Benjamini-
Hochberg procedure to keep the false discovery rate
(FDR) at 5% [34].
To evaluate NEWS2 and identify parameters that
could improve prediction of severe COVID-19 outcomes
(objectives 2 and 3), we used regularised logistic regres-
sion with a least absolute shrinkage and selection
operator (LASSO) estimator that shrinks parameters
according to their variance, reduces overfitting, and en-
ables automatic variable selection [35]. The optimal
degree of regularisation was determined by identifying a
tuning parameter λ using cross-validation. To avoid
overfitting and to reduce the number of false-positive
predictors, λ was selected to give a model with an area
under the receiver operating characteristic curve (AUC)
one standard error below the ‘best’ model. To evaluate
the predictive performance of our model on new cases
of the same underlying population (internal validation),
we performed nested cross-validation (10-folds the for
inner loop; 10-folds/1000 repeats for the outer loop).
Discrimination was assessed using AUC and Brier score.
Missing feature information was imputed using k-nearest
neighbour (kNN) imputation (k = 5). All steps (feature
selection, winsorizing, scaling, and kNN imputation)
were incorporated within the model development and
selection process to avoid data leakage that would other-
wise result in optimistic performance measures [36]. All
analyses were conducted with Python 3.8 [31] using the
statsmodels [37] and Scikit-Learn [38] packages.
We evaluated the transportability of the derived regu-
larised logistic regression model in external validation
samples from GSTT (n = 988), UHS (n = 633), UHBW
(n = 190), UCH (n = 411), UHB (n = 1037), OUH (n =
163), and Wuhan (n = 2815). Validation used LASSO lo-
gistic regression models trained on the KCH training
sample, with code and pre-trained models shared via
GitHub.1 Models were assessed in terms of discrimin-
ation (AUC, sensitivity, specificity, Brier score), calibra-
tion, and clinical utility (decision curve analysis, number
needed to evaluate) [32, 39]. Moderate calibration was
assessed by plotting model-predicted probabilities (x-
axis) against observed proportions (y-axis) with locally
estimated scatterplot smoothing (LOESS) and logistic
curves [40]. Clinical utility was assessed using decision
curve analysis where ‘net benefit’ was plotted against a
range of threshold probabilities. Unlike diagnostic per-
formance measures, decision curves incorporate prefer-
ences of the clinician and patient. The threshold
probability (pt) is where the expected benefit of treat-
ment is equal to the expected benefit of avoiding treat-
ment [41]. Net benefit was calculated by counting the
number of true positives (predicted risk > pt and experi-
enced severe COVID-19 outcome) and false positives
(predicted risk > pt but did not experience severe
COVID-19 outcome) and using the below formula:







Our model was developed as a screening tool, to iden-
tify at hospital admission patients at risk of more severe
outcomes. The intended treatment for patients with a
positive result from this model would be further examin-
ation by a clinician, who would make recommendations
regarding appropriate treatment (e.g. earlier transfer to
the ICU, intensive monitoring, treatment). We compared
the decision curve from our model to two extreme cases
of ‘treat none’ and ‘treat all’. The ‘treat none’ (i.e. routine
management) strategy implies that no patients would be
1https://github.com/ewancarr/NEWS2-COVID-19
Carr et al. BMC Medicine           (2021) 19:23 Page 5 of 16
selected for further examination by a clinician; the ‘treat
all’ strategy (i.e. intensive management) implies that all
patients would undergo further assessment. A model is
clinically beneficial if the model-implied net benefit is
greater than either the ‘treat none’ or ‘treat all’ strategies.
Since the intended strategy involves a further examin-
ation by a clinician, and is therefore low risk, our
emphasis throughout is on avoiding false negatives (i.e.
failing to detect a severe case) at the expense of false
positives. We therefore used thresholds of 30% and 20%
(for 14-day and 3-day outcomes, respectively) to
calculate sensitivity and specificity. This gave a better
balance of sensitivity vs. specificity and reflected the
clinical preference to avoid false negatives for the pro-
posed screening tool.
Sensitivity analyses
We conducted five sensitivity analyses. First, to explore
the ability of NEWS2 to predict shorter-term severe
COVID-19 outcome, we developed models for ICU
transfer/death at 3 days following hospital admission. All
steps described above were repeated, including training
(feature selection) and external validation. Second, fol-
lowing recent studies suggesting sex differences in
COVID-19 outcome [18], we tested interactions between
each physiological and blood parameters and sex using
likelihood-ratio tests. Third, we repeated all models with
adjustment for ethnicity in the subset of individuals with
available data for ethnicity (n = 960 in the KCH training
sample). Fourth, to explore the differences between
community-acquired vs. nosocomial infection, we re-
peated all models after excluding 153 nosocomial pa-
tients (n = 1123). Finally, we considered an alternative
baseline model of ‘NEWS2 only’. Our primary analyses
used a baseline model of ‘NEWS2 + age’ because
NEWS2 is rarely used in isolation for prognostication
and treatment decisions will incorporate other patient
characteristics such as age.
Results
Descriptive analyses
The KCH training cohort comprised 1276 patients ad-
mitted with a confirmed diagnosis of COVID-19 (from 1
March to 31 April 2020) of whom 389 (31%) were trans-
ferred to the ICU or died within 14 days of hospital
admission, respectively. The validation cohorts com-
prised 6237 patients across seven sites. At UK NHS
trusts, 30 to 42% of patients were transferred to the ICU
or died within 14 days of admission. Disease severity was
lower in the Wuhan sample, where 4% were transferred
to the ICU or died. Table 1 presents the demographic
and clinical characteristics of the training and validation
cohorts. The UK sites were similar in terms of age and
sex, with patients tending to be older (median age 59–
74) and male (58 to 63%) but varied in the proportion of
patients of non-White ethnicity (from 10% at UHS to
40% at KCH and UCH). Blood and physiological param-
eters were broadly consistent across UK sites.
Logistic regression models were used to assess inde-
pendent associations between each variable and severe
COVID-19 outcome (ICU transfer/death) in the KCH
cohort. Additional file 3: Table S3 presents odds ratios
adjusted for age and sex (model 1) and comorbidities
(model 2), sorted by effect size. Increased odds of trans-
fer to the ICU or death by 14 days were associated with
NEWS2 score, oxygen flow rate, respiratory rate, CRP,
neutrophil count, urea, neutrophil/lymphocyte ratio,
heart rate, and temperature. Reduced odds of severe out-
comes were associated with lymphocyte/CRP ratio, oxy-
gen saturation, estimated GFR, and albumin.
Evaluating NEWS2 score for prediction of severe COVID-
19 outcome
Logistic regression models were used to evaluate a base-
line model containing hospital admission NEWS2 score
and age for the prediction of severe COVID-19 out-
comes at 14 days. Internally validated discrimination for
the KCH training sample was moderate (AUC = 0.700;
95% confidence interval (CI) 0.680, 0.722; Brier score =
0.192; 0.186, 0.197; Table 2). Discrimination remained
poor-to-moderate in UK validation sites (AUC = 0.623 to
0.729) but was moderate-to-good in Norway (AUC =
0.786) and Wuhan hospitals (AUC= 0.815) (Figs. 1 and 2).
Calibration was inconsistent with risks underestimated in
some sites (UHS, GSTT) and overestimated in others
(UHBW, UHB; Fig. 2).
Supplementing NEWS2 with routinely collected blood and
physiological parameters
We considered whether routine blood and physiological
parameters could improve risk stratification for
medium-term COVID-19 outcome (ICU transfer/death
at 14 days). When adding demographic, blood, and
physiological parameters to NEWS2, nine features were
retained following LASSO regularisation, in order of
effect size: NEWS2 score, supplemental oxygen flow
rate, urea, age, oxygen saturation, CRP, estimated GFR,
neutrophil count, and neutrophil/lymphocyte ratio. Not-
ably, comorbid conditions were not retained when added
in subsequent models, suggesting most of the variance
explained was already captured by the included parame-
ters. Internally validated discrimination in the KCH
training sample was moderate (AUC = 0.735; 95% CI
0.715, 0.757) but improved compared to ‘NEWS2 + age’
(Table 2). This improvement over NEWS2 alone was
replicated in validation samples (Fig. 1). The supple-
mented model continued to show evidence of substantial
miscalibration.
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Sensitivity analyses
For the 3-day endpoint, 13% of patients at KCH (n =
163) and between 16 and 29% of patients in the UK
and Norway were transferred to the ICU or died
(Table 1). The 3-day model retained just two parame-
ters following regularisation: NEWS2 score and sup-
plemental oxygen flow rate. For the baseline model
(‘NEWS2 + age’), discrimination was moderate at in-
ternal validation (AUC = 0.764; 95% CI 0.737, 0.794;
Additional file 4: Table S4) and external validation
(AUC = 0.673 to 0.755), but calibration remained poor
(Additional file 5: Figure S1). Moreover, the supple-
mented model (‘NEWS2 + oxygen flow rate’) showed
smaller improvements in discrimination compared to
those seen at 14 days. For the KCH training cohort,
internally validated AUC increased by 0.025: from
0.764 (95% CI 0.737, 0.794) for ‘NEWS2 + age’ to
0.789 (0.763, 0.819) for the supplemented model
(‘NEWS2 + oxygen flow rate’). At external validation,
improvements were modest (UHBW, OUH) or nega-
tive (GSTT) in some sites, but more substantial in
others (UHS, UCH). Moreover, model calibration was
considerably worse for the supplemented 3-day model
(Additional file 5: Figure S1).
We found no evidence of difference by sex (results not
shown) and the findings were consistent when addition-
ally adjusting for ethnicity in the subset of individuals
with ethnicity data and when excluding nosocomial
patients (Additional file 6: Table S5). Discrimination for
the alternative baseline model of ‘NEWS2 only’
(Additional file 7: Table S6) showed a similar pattern of
results as those for ‘NEWS2 + age’, except that improve-
ments in discrimination for the supplemented model
(‘All features’) were larger in most sites.
Decision curve analysis
Decision curve analysis for the 14-day endpoint is pre-
sented in Fig. 3. At KCH, the baseline model (‘NEWS2 +
age’) offered small increments in net benefit compared
to the ‘treat all’ and ‘treat none’ strategies for risk thresh-
olds in the range 25 to 60%. This was replicated in all
validation cohorts except for UHBW and OUH where
the net benefit for ‘NEWS2 + age’ was lower than the
‘treat none’ strategy beyond the 40% risk threshold. The
supplemented model (‘All features’) improved upon
‘NEWS2 + age’ and the two default strategies in most
sites across the range 20 to 80%, except for (i) UHBW,
where ‘treat none’ was superior beyond thresholds of
Table 2 KCH internally validated predictive performance (n = 1276) based on nested repeated cross-validation
NEWS2 + age, mean (95% CI) All features, mean (95% CI)
14-day ICU/death AUC 0.700 [0.680, 0.722] 0.735 [0.715, 0.757]
Brier score 0.192 [0.186, 0.197] 0.183 [0.177, 0.189]
Sensitivity1 0.778 [0.747, 0.815] 0.735 [0.702, 0.772]
Specificity1 0.478 [0.445, 0.509] 0.592 [0.562, 0.621]
1Calculated at 30% probability threshold. AUC based on repeated, nested cross-validation (inner loop, 10-folds; outer loop = 10-folds/1000 repeats). Missing values
imputed at each outer loop with k-nearest neighbour (kNN) imputation
Fig. 1 Improvement in the area under the curve (AUC) for supplemented NEWS2 model for 14-day ICU/death at training and validation sites
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55%, and (ii) GSTT, where ‘treat all’ was superior up to
a threshold of 30% and no improvement was seen for
the supplemented model.
For the 3-day endpoint, the improvement in net
benefit for the supplemented model over the two de-
fault strategies was smaller, compared to the im-
provements seen at 14 days (Additional file 8: Figure
S2). At three sites (UHBW, GSST, and Wuhan), nei-
ther the baseline (‘NEWS2 + age’) nor the supple-
mented (‘All features’) models offered any
improvement over the ‘treat all’ or ‘treat none’ strat-
egies. At KCH and UHS, net benefit for ‘NEWS2 +
age’ was higher than the default strategies for a
range of risk thresholds but was not increased fur-




This study is amongst the first to systematically evaluate
NEWS2 for severe COVID-19 outcome and carry out
external validation at multiple international sites (five
UK NHS Trusts, one hospital in Norway, and two
hospitals in Wuhan, China). We found that while
‘NEWS2 + age’ had moderate discrimination for short-
term COVID-19 outcome (3-day ICU transfer/death), it
showed poor-to-moderate discrimination for the
medium-term outcome (14-day ICU transfer/death).
Thus, while NEWS2 may be effective for short-term (e.g.
24 h) prognostication, our results question its suitability
as a screening tool for medium-term COVID-19 out-
come. Risk stratification was improved by adding rou-
tinely collected blood and physiological parameters, and
Fig. 2 Calibration (logistic and LOESS curves) of supplemented NEWS2 model for 14-day ICU/death model at validation sites
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discrimination in supplemented models was moderate-
to-good. However, the model showed evidence of misca-
libration, with a tendency to underestimate risks in
external sites. The derived model for 14-day ICU trans-
fer/death included nine parameters: NEWS2 score, sup-
plemental oxygen flow rate, urea, age, oxygen saturation,
CRP, estimated GFR, neutrophil count, and neutrophil/
lymphocyte ratio. Notably, pre-existing comorbidities
did not improve risk prediction and were not retained in
the final model. This was unexpected but may indicate
that the effect of pre-existing health conditions could be
manifest through some of the included blood or physio-
logical markers.
Overall, this study overcomes many of the factors
associated with a high risk of bias in the develop-
ment of prognostic models for COVID-19 [13] and
provides some evidence to support the supplementa-
tion of NEWS2 for clinical decisions with these
patients.
Comparison with other studies
A systematic review of 10 prediction models for mortal-
ity in COVID-19 infection [10] found broad similarities
with the features retained in our models, particularly re-
garding CRP and neutrophil levels. However, existing
prediction models suffer several methodological
Fig. 3 Net benefit of supplemented NEWS2 model for 14-day ICU/death compared to default strategies (‘treat all’ and ‘treat none’) at training and
validation sites
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weaknesses including overfitting, selection bias, and reli-
ance on cross-sectional data without accounting for
censoring. Additionally, many existing studies have re-
lied on single-centre or ethnically homogenous Chin-
ese cohorts, whereas the present study shows
validation across multiple and diverse populations. A
key strength of our study is the robust and repeated
external validation across national and international
sites; however, evidence of miscalibration suggests we
should be cautious when attempting to generalise
these findings. Future research should include larger
collaborations and aim to develop ‘from onset’ popu-
lation predictions.
NEWS2 is a summary score derived from six
physiological parameters, including oxygen supple-
mentation. Lack of evidence for NEWS2 use in
COVID-19 especially in primary care has been
highlighted [9]. The oxygen saturation component of
physiological measurements added value beyond
NEWS2 total score and was retained following regu-
larisation for 14-day endpoints. This suggests some
residual association over and above what is captured
by the NEWS2 score and reinforces Royal College of
Physicians guidance that the NEWS2 score ceilings
with respect to respiratory function [42].
Cardiac disease and myocardial injury have been de-
scribed in severe COVID-19 cases in China [2, 23]. In
our model, blood Troponin-T, a marker of myocardial
injury, had additional salient signal but was only mea-
sured in a subset of our cohort at admission, so it was
excluded from our final model. This could be explored
further in larger datasets.
Strengths and limitations
Our study provides a risk stratification model for which
we obtained generalisable and robust results across
seven national and international sites with differing geo-
graphical catchment and population characteristics. It is
amongst the first to evaluate NEWS2 at hospital admis-
sion for severe COVID-19 outcome and amongst a
handful to externally validate a supplemented model
across multiple sites.
However, some limitations must be acknowledged.
First, there are likely to be other parameters not mea-
sured in this study that could substantially improve
the risk stratification model (e.g. radiological features,
obesity, or comorbidity load). These parameters could
be explored in future work but were not considered
in the present study to avoid limiting the real-world
implementation of the risk stratification model. Sec-
ond, our models showed better performance in UK
secondary care settings amongst populations with
higher rates of severe COVID-19 disease. Therefore,
further research is needed to investigate the suitability
of our model for primary care settings which have a
high prevalence of mild disease severities and in com-
munity settings. This would allow us to capture vari-
ability at earlier stages of the disease and trends in
patients not requiring hospital admission. Third, while
external validation across multiple national and inter-
national sites represents a key strength, we did not
have access to individual participant data and model
development was limited to a single site (KCH). Al-
though we benefited from existing infrastructure to
support rapid data analysis, we urgently need infra-
structure to support data sharing between sites to ad-
dress some of the limitations of the present study
(e.g. miscalibration) and improve the transferability of
these models. Not only would this facilitate external
validation, but more importantly, it would allow
multi-site prediction models to be developed using
pooled, individual participant data [43]. Fourth, our
analyses would have excluded patients who experi-
enced severe COVID-19 outcome at home or at an-
other hospital, after being discharged from a
participating hospital. Fifth, our model was restricted
to blood and physiological parameters measured at
hospital admission. This was by design and reflected
the aim of developing a screening tool for risk strati-
fication at hospital admission. However, future studies
should explore the extent to which risk stratification
could be improved by incorporating repeated mea-
sures of NEWS2 and relevant biomarkers.
Conclusions
The NEWS2 early warning score is in near-universal
use in UK NHS Trusts since March 2019 [15], but
little is known about its use for COVID-19 patients.
Here, we showed that NEWS2 and age at hospital
admission had poor-to-moderate discrimination for
medium-term (14-day) severe COVID-19 outcome,
questioning its use as a tool to guide hospital admis-
sion. Moreover, we showed that NEWS2 discrimin-
ation could be improved by adding eight blood and
physiological parameters (supplemental oxygen flow
rate, urea, age, oxygen saturation, CRP, estimated
GFR, neutrophil count, neutrophil/lymphocyte ratio)
that are routinely collected and readily available in
healthcare services. Thus, this type of model could
be easily implemented in clinical practice, and pre-
dicted risk score probabilities of individual patients
are easy to communicate. At the same time, al-
though we provided some evidence of improved dis-
crimination vs. NEWS2 and age alone, given
miscalibration in external sites, our proposed model
should be used as a complement and not as a re-
placement for clinical judgement.
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